Markus Meriläinen

Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)

Janet A. Thomas, Harvey L. Levy, Stephen Amato et al. · Molecular Genetics and Metabolism · 2018 · 183 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +10

Patient‐directed titration for achieving glycaemic goals using a once‐daily basal insulin analogue: an assessment of two different fasting plasma glucose targets ‐ the TITRATE ^TM study

Lawrence Blonde, Markus Meriläinen, Vatsala Karwe et al. · Diabetes Obesity and Metabolism · 2009 · 181 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study*

L. F. Meneghini, Kirsten Rosenberg, Christoph Koenen et al. · Diabetes Obesity and Metabolism · 2006 · 100 citations · Full text

Medicine, Endocrinology, Internal Medicine +17

Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial

Cary O. Harding, Roberto Amato, Mary Stuy et al. · Molecular Genetics and Metabolism · 2018 · 85 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal‐only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14‐week follow‐up data from PREDICTIVE™

Anne Dornhorst, H.‐J. Lüddeke, Christoph Koenen et al. · Diabetes Obesity and Metabolism · 2007 · 56 citations

Medicine, Endocrinology, Pharmacotherapy +17